Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1182-1188

  Taraboletti, Giulia ^a   Micheletti, Gianluca ^a   Rieppi, Monica ^a   Poli, Maura ^a   Turatto, Michele ^a   Rossi, Cosmo ^c   Borsotti, Patrizia ^a   Roccabianca, Paola ^b   Scanziani, Eugenio ^b   Nicoletti, Maria Ines ^a   Bombardelli, Ezio ^d   Morazzoni, Paolo ^d   Riva, Antonella ^d   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Consorzio Mario Negri Sud ^*  (Italy)

^d INDENA S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

13 (N BUTOXYCARBONYL BETA ISOBUTYLISOSERINOYL) 10 DEHYDRO 10 DEACETYL C SECOBACCATIN; 14BETA HYDROXY 10 DEACETYLBACCATIN 3 DERIVATIVE; ANGIOGENESIS INHIBITOR; BACCATIN III; DOCETAXEL; FIBROBLAST GROWTH FACTOR 2; IDN 5102; IDN 5106; IDN 5111; IDN 5127; IDN 5390; IDN 5451; IDN 5452; IDN 5476; MATRIGEL; ORTATAXEL; PACLITAXEL; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MOTILITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MICROTUBULE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CELL DIVISION; CELL LINE; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PHYSIOLOGIC; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS; TIME FACTORS; TUBULIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036554920     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
2. Brower, V. Tumor angiogenesis-new drugs on the block. Nat. Biotechnol., 17: 963-968, 1999.
3. Giavazzi, R., and Taraboletti, G. Angiogenesis and angiogenesis inhibitors in cancer. Forum (Genova), 9: 261-272, 1999.
4. Taraboletti, G., and Margosio, B. Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol., 1: 378-384, 2001.
5. Chaplin, D. J., and Dougherty, G. J. Tumour vasculature as a target for cancer therapy. Br. J. Cancer, 80 (Suppl. 1): 57-64, 1999.
6. Jordan, M. A., and Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol., 10: 123-130, 1998.
7. Wood, K. W., Cornwell, W. D., and Jackson, J. R. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Pharmacol., 1: 370-377, 2001.
8. Iyer, S., Chaplin, D. J., Rosenthal, D. S., Boulares, A. H., Li, L. Y., and Smulson, M. E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res., 58: 4510-4514, 1998.
9. Blakey, D. C., Curry, B., Westwood, F. R., and Ashton, S. E. Vascular targeting activity of ZD6126 in two tumor models growing in athymic rats. Proc. Am. Assoc. Cancer Res., 42: 823, 2001.
10. Miller, K. D., Sweeney, C. J., and Sledge, G. W., Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol., 19: 11951206, 2001.
11. Blagosklonny, M. V., and Fojo, T. Molecular effects of paclitaxel: myths and reality (a critical review). Int. J. Cancer, 83: 151-156, 1999.
12. Dumontet, C. Mechanisms of action and resistance to tubulinbinding agents. Expert Opin. Investig. Drugs, 9: 779-788, 2000.
13. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., and Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 2: 1843-1849, 1996.
14. Klauber, N., Parangi, S., Flynn, E., Hamel, E., and D'Amato, R. J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res., 57: 81-86, 1997.
15. Lau, D. H., Xue, L., Young, L. J., Burke, P. A., and Cheung, A. T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm., 14: 31-36, 1999.
16. Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., and Sledge, G. W., Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res., 61: 3369-3372, 2001.
17. Appendino, G., Danieli, B., Jakupoviv, J., Belloro, E., Scambia, G., and Bombardelli, E. Synthesis and evaluation of C-seco paclitaxel analogues. Tetrahedron Lett., 38: 4273-4276, 1997.
18. Nicoletti, M. I., Colombo, T., Rossi, C., Monardo, C., Stura, S., Zucchetti, M., Riva, A., Morazzoni, P., Donati, M. B., Bombardelli, E., D'Incalci, M., and Giavazzi, R. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res., 60: 842-846, 2000.
19. Giannakakou, P., Sackett, D. L., Kang, Y. K., Zhan, Z., Buters, J. T., Fojo, T., and Poruchynsky, M. S. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem., 272: 17118-17125, 1997.
20. Belotti, D., Rieppi, M., Nicoletti, M. I., Casazza, A. M., Fojo, T., Taraboletti, G., and Giavazzi, R. Paclitaxel (Taxol®) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin. Cancer Res., 2: 1725-1730, 1996.
21. Chirivi, R. G., Garofalo, A., Crimmin, M. J., Bawden, L. J., Stoppacciaro, A., Brown, P. D., and Giavazzi, R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer, 58: 460-464, 1994.
22. Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., Pauly, R. R., Grant, D. S., and Martin, G. R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Investig., 67: 519-528, 1992.
23. Valoti, G., Nicoletti, M. I., Pellegrino, A., Jimeno, J., Hendriks, H., D'Incalci, M., Faircloth, G., and Giavazzi, R. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res., 4: 1977-1983, 1998.
24. Giavazzi, R., and Garofalo, A. Syngeneic murine metastasis models. B16 melanoma. In: S. A. Brooks and U. Schumacher (eds.), Metastasis Research Protocols, Vol. 2, pp. 223-229. Totowa, NJ: Humana Press, 2001.
25. Schirner, M. Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev., 19: 67-73, 2000.
26. Distefano, M., Scambia, G., Ferlini, C., Gaggini, C., De Vincenzo, R., Riva, A., Bombardelli, E., Ojima, I., Fattorossi, A., Panici, P. B., and Mancuso, S. Anti-proliferative activity of a new class of taxanes (14βhydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistancepositive human cancer cells. Int. J. Cancer, 72: 844-850, 1997.
27. Kingston, D. G. Recent advances in the chemistry of Taxol. J. Nat. Prod., 63: 726-734, 2000.
28. Derry, W. B., Wilson, L., Khan, I. A., Luduena, R. F., and Jordan, M. A. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry, 36: 3554-3562, 1997.
29. Rosenbaum, J. Cytoskeleton: functions for tubulin modifications at last. Curr. Biol., 10: R801-R803, 2000.
30. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
31. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Investig., 105: R15-R24, 2000.